Clene Inc. (CLNN)

NASDAQ
8.36
+0.56(+7.18%)
  • Volume:
    150,860
  • Bid/Ask:
    8.23/8.38
  • Day's Range:
    7.93 - 8.48

CLNN Overview

Prev. Close
7.8
Day's Range
7.93-8.48
Revenue
420K
Open
7.88
52 wk Range
6.23-17.82
EPS
-1.53
Volume
150,860
Market Cap
464.68M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
465,831
P/E Ratio
-
Beta
-
1-Year Change
-28.31%
Shares Outstanding
59,574,382
Next Earnings Date
Dec 01, 2021
What is your sentiment on Clene Inc.?
or
Vote to see community's results!

Clene Inc. News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell

Clene Inc. Company Profile

Clene Inc. Company Profile

Sector
Services
Employees
63

Clene Inc, formerly Chelsea Worldwide Inc., is a clinical-stage biopharmaceutical company. The Company through its subsidiary, Clene Nanomedicine, Inc., is focused on the development of therapeutics for neurodegenerative diseases. The Company has innovated a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. It has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The Company’s pipeline includes CNM-Au8, CNM-ZnAg, CNM-AgZn-17 and CNM-AuPt7. Its CNM-Au8 is a bioenergetic nanocatalyst, which enhances critical intracellular bioenergetic reactions necessary for repairing and reversing neuronal damage. CNM-AgZn17 is a topical gel polymer suspension of silver and zinc ions. Its CNM-PtAu7 is gold-platinum clean surfaced nanotechnology (CSN) therapeutic, which aims to address the unmet medical needs in several disease areas.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.